Opioid manufacturers have suffered a number of setbacks over the last several weeks. The FDA asked Endo Pharmaceuticals, in June, to stop the sale of Opana ER, an “extended-release” opioid pain reliever (OPR). If not, the agency promised it would no longer approve the drug. Endo indicated it would fully consider the request before acting. Then on … [Read more...]